San Diego-based Illumina (NASDAQ: [[ticker:ILMN]]), the market-leading maker of gene sequencing instruments, said today that its sales climbed 36 percent, to $287.5 million, in the quarter that ended June 30. The company turned a profit of $30.6 million in the quarter, a 2.7 percent increase compared with the $29.8 million profit in the same period a year earlier. Spending on R&D climbed by 16 percent, and sales, general and administrative costs rose by 30 percent to $69.2 million, the company said.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
